Advanced Oncotherapy, the developer of cancer treatment proton therapy systems, has announced that Lord David Evans has stepped down from the Board with immediate effect, who’s place will be filled by Professor Stephen Myers.
Professor Steve Myers OBE, was appointed Executive Chairman of Advanced Oncotherapy’s fully owned subsidiary ADAM S.A. (ADAM) a year ago and, since then, has delivered with the ADAM team significant progress in designing and developing the Company’s next-generation proton beam cancer therapy technology, the ground-breaking LIGHT system.
Professor Myers was Head of Medical Applications at CERN in Geneva from 2014 until 2016. From 2009-2013, he was the Director of Accelerators and Technology, where he was responsible for the operation and exploitation of the whole CERN accelerator complex, with particular emphasis on the Large Hadron Collider (LHC) and for the development of the new projects and technologies.
In 2012, he was elected as a Fellow of the Royal Academy of Engineering which honours the UK’s most eminent engineers, and is a Fellow of the Institute of Physics, the European Physical Society and International Fellow of the American Physical Society. He is internationally recognised for his engineering contributions and leadership in the development of CERN’s particle colliders over the past 40 years, including the Intersecting Storage Ring Accelerator, the Large Electron-Positron collider and the LHC.
Mike Sinclair, Executive Chairman of Advanced Oncotherapy, said: “We are very pleased with the proposed appointment of Professor Steve Myers to the Board. Since his appointment at ADAM, Professor Steve Myers has provided the Company with invaluable advice and extensive knowledge. We are extremely lucky to have someone of his calibre joining the board of Advanced Oncotherapy. On behalf of the Board, I would like to thank Lord Evans for his hard work and dedication over the years, and wish him every success in the future. David has been involved with the Company since its inception and has made a significant contribution to our development in terms of both his commercial and political prowess, and for which we are very grateful.”
Prof. Stephen Myers, said: “I am very pleased to be part of Advanced Oncotherapy, both asExecutive Chairman of ADAM and in the future as member of the Board of Advanced Oncotherapy. This represents a unique opportunity and I look forward to sharing further my own experience and knowledge of the industry with the company.”